BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21821852)

  • 1. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.
    Maniadakis N; Ekman M; Calvert MJ; Freemantle N; Karamalis M; Vardas P
    Europace; 2011 Nov; 13(11):1597-603. PubMed ID: 21821852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
    Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
    Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
    Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
    Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
    Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial.
    Blomström P; Ekman M; Lundqvist CB; Calvert MJ; Freemantle N; Lönnerholm S; Wikström G; Jönsson B
    Eur J Heart Fail; 2008 Sep; 10(9):869-77. PubMed ID: 18684664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina.
    Poggio R; Augustovsky F; Caporale J; Irazola V; Miriuka S
    Int J Technol Assess Health Care; 2012 Oct; 28(4):429-35. PubMed ID: 23006489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac resynchronization therapy: a cost or an investment?
    Boriani G; Mantovani LG; Biffi M; Schalij MJ; Martignani C; Leclercq C; Bax JJ; Auricchio A
    Europace; 2011 May; 13 Suppl 2():ii32-8. PubMed ID: 21518747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain.
    Almenar L; Díaz B; Quesada A; Crespo C; Martí B; Mealing S; Linde C; Daubert C
    Int J Technol Assess Health Care; 2013 Apr; 29(2):140-6. PubMed ID: 23552131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
    Banz K;
    Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyssynchrony, contractile function, and response to cardiac resynchronization therapy.
    Knappe D; Pouleur AC; Shah AM; Cheng S; Uno H; Hall WJ; Bourgoun M; Foster E; Zareba W; Goldenberg I; McNitt S; Pfeffer MA; Moss AJ; Solomon SD;
    Circ Heart Fail; 2011 Jul; 4(4):433-40. PubMed ID: 21602574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is cardiac resynchronization therapy cost-effective?
    Boriani G; Biffi M; Martignani C; Valzania C; Diemberger I; Bertini M; Domenichini G; Ziacchi M; Branzi A
    Europace; 2009 Nov; 11 Suppl 5():v93-7. PubMed ID: 19861398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system.
    Bertoldi EG; Rohde LE; Zimerman LI; Pimentel M; Polanczyk CA
    Int J Cardiol; 2013 Mar; 163(3):309-315. PubMed ID: 21704396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
    Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of a randomized trial of biventricular pacing in Canada.
    Bentkover JD; Dorian P; Thibault B; Gardner M
    Pacing Clin Electrophysiol; 2007 Jan; 30(1):38-43. PubMed ID: 17241313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure.
    Tomini F; Prinzen F; van Asselt AD
    Eur J Health Econ; 2016 Dec; 17(9):1159-1172. PubMed ID: 26728985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.